Target intelligence / Profile preview

Jun activation domain-binding protein 1 (JAB1)

Target
JAB1
Molecular classification
Other, specifically “COP9 signalosome subunit”, Protein-protein interaction regulator, Deneddylase (metalloprotease, MPN family)
01

Overview

Jun activation domain-binding protein 1 (JAB1), also known as COP9 signalosome complex subunit 5 (CSN5), is a multifunctional protein that is a central component of the COP9 signalosome complex. It acts as a deneddylase, removing the ubiquitin-like modifier NEDD8 from Cullin family scaffold proteins, thus regulating the activity of Cullin-RING E3 ubiquitin ligases. JAB1 directly interacts with the Jun activation domain, influencing transcription and protein stability. It is essential in regulating protein degradation and stability, especially of receptor proteins such as the interferon receptor, facilitating optimal interferon signaling by limiting receptor proteolysis. JAB1 plays crucial roles in immune regulation, cell signaling, and is implicated in disease processes including cancer and inflammation, generally through its broad control of protein homeostasis and signaling[2]. - Unlike “Transcription factor Jun” (encoded by JUN or c-Jun)[1][3][4][5], JAB1 is not itself a transcription factor but a regulator of various proteins including transcription factors and receptors, through modulation of ubiquitin-proteasome system function.

Other names
COP9 signalosome complex subunit 5 (CSN5)JAB1Jun activation domain-binding protein 1
02

Mechanism of action

Regulation of protein stability through COP9 signalosome-mediated deneddylation of Cullin family proteins, stabilization of cytokine/IFN receptors by antagonizing NEDD8 modification and SCF E3 ligase activity[2]

03

Biological functions

Signal transductionProtein degradationRegulation of ubiquitin-proteasome systemImmune responseRegulation of interferon receptor stability
04

Disease associations

CancerInflammationImmune diseaseOther
05

Safety considerations

Not well established; theoretical risk related to generalized modulation of protein turnover and immune signaling. Potential implications in overactivation or suppression of cytokine signaling, ubiquitin-proteasome dysfunction, and general cell cycle dysregulation if targeted systemically.
06

Interacting drugs

None reported directly; indirect interaction possible via NEDD8-activating enzyme inhibitors
07

Biomarkers

None reported; possible role in IFN response modulation as a biomarker for immune and cancer therapeutics

Beyond the preview

Go deeper on Jun activation domain-binding protein 1 (JAB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jun activation domain-binding protein 1 (JAB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call